Baricitinib in Dermatology: Expanding Therapeutic Horizons Beyond Alopecia Areata
Bibliographic record
Abstract
Context: Janus kinases (JAK), in coordination with signal transducer and activator of transcription (STAT) proteins, form a network of pathogenic pathways that regulate inflammatory immune responses. Dysregulation of the JAK-STAT pathway has been implicated in the pathogenesis of numerous inflammatory dermatoses. Consequently, JAK inhibitors have emerged as a novel therapeutic modality in dermatology. This narrative review aims to summarize the current evidence on baricitinib, a first-generation JAK inhibitor, focusing on its efficacy, safety, and therapeutic applications in dermatological diseases, particularly alopecia areata (AA) and atopic dermatitis (AD). The review also explores its emerging and off-label uses in other chronic, treatment-refractory dermatoses. Evidence Acquisition: A comprehensive literature search was conducted across PubMed, Scopus, and Google Scholar using predefined keywords: “baricitinib in dermatology”, “baricitinib in alopecia areata”, and “efficacy of baricitinib in dermatological conditions”. Data from systematic reviews, randomized controlled trials (RCTs), case series, and case reports were included. Additional information was derived from United States Food and Drug Administration (FDA) approval documents, ClinicalTrials.gov, and the prescribing leaflet. Particular emphasis was placed on evaluating the drug’s accessibility and relevance within the Indian clinical context. Results: Baricitinib received FDA approval on June 13, 2022, for the treatment of moderate to severe AA, marking a significant advancement in targeted immunotherapy. It has also demonstrated efficacy in AD and was extensively utilized during the COVID-19 pandemic due to its antiviral and anti-inflammatory properties. Emerging evidence supports its potential in refractory conditions such as vitiligo, dermatomyositis, systemic sclerosis, lichen planus, and pyoderma gangrenosum, though further prospective studies are warranted. Conclusions: Baricitinib represents a major advancement in the management of immune-mediated dermatologic diseases. Its expanding clinical utility underscores the importance of continued research to optimize dosing strategies, evaluate long-term safety, and define its role across a broader spectrum of inflammatory skin disorders.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".